Detalles de la búsqueda
1.
BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.
Br J Cancer
; 109(6): 1593-8, 2013 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23799845
2.
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
Leukemia
; 21(7): 1481-7, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17476280
3.
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Leukemia
; 20(4): 664-70, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16482210
4.
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.
Leukemia
; 20(11): 1925-30, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16990771
5.
A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.
Sci Rep
; 7(1): 2467, 2017 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28550306
6.
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Leukemia
; 17(5): 821-8, 2003 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-12750692
7.
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Leukemia
; 17(12): 2401-9, 2003 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-14523461
8.
Indirect sandwich enzyme-linked immunosorbent assay (ELISA) for plasma apolipoprotein E.
Ann Clin Biochem
; 33 ( Pt 2): 119-26, 1996 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-8729719
9.
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.
Leukemia
; 31(11): 2529-2531, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28862704
10.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Leukemia
; 26(9): 2096-102, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22446502
11.
e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
Leukemia
; 19(4): 681-4, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15703785
12.
Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale.
Blood Cancer J
; 1(3): e13, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22829126
13.
Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene.
Leukemia
; 30(6): 1402-5, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26503642
14.
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Int J Lab Hematol
; 32(6 Pt 1): e222-8, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20491997
15.
Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
Leukemia
; 29(1): 230-2, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25179732
16.
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Leukemia
; 24(10): 1719-24, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20811403
17.
Harmonization of molecular monitoring of CML therapy in Europe.
Leukemia
; 23(11): 1957-63, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19710700
18.
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Leukemia
; 23(9): 1628-33, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19641527
19.
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Leukemia
; 23(6): 1054-61, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19282833
20.
Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.
Br J Haematol
; 107(3): 587-99, 1999 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-10583264